Nitrase Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$45M
- Investors
-
10
Nitrase Therapeutics General Information
Description
Developer of a biopharmaceutical platform designed to identify nitrases and their nitro-substrates and understand their role in disease. The company's platform is based on knowledge of protein nitration and the enzymatic activity of nitrases, enabling medical professionals to develop small-molecule drugs and antibodies targeting core biological processes in diseases such as Parkinson's disease and cancer.
Contact Information
Website
www.nitrasetx.comCorporate Office
- 1 Corporate Drive
- South San Francisco, CA 94080
- United States
Corporate Office
- 1 Corporate Drive
- South San Francisco, CA 94080
- United States
Nitrase Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 02-Nov-2021 | $45M | Completed | Generating Revenue | ||
| 4. Accelerator/Incubator | 07-Sep-2018 | Completed | Generating Revenue | |||
| 3. Seed Round | 12-Jul-2018 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2018 | $2.5K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Startup |
Nitrase Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nitrase Therapeutics Comparisons
Industry
Financing
Details
Nitrase Therapeutics Competitors (15)
One of Nitrase Therapeutics’s 15 competitors is GlycosBio, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GlycosBio | Venture Capital-Backed | Houston, TX | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| PlantForm | Venture Capital-Backed | Toronto, Canada | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA |
Nitrase Therapeutics Patents
Nitrase Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026124614-A1 | Methods of treating disorders | Pending | 13-Dec-2024 | ||
| AU-2025250241-A1 | Ny39 alpha-synuclein antibodies and methods of use thereof | Pending | 02-Apr-2024 | ||
| WO-2025212730-A1 | Ny39 alpha-synuclein antibodies and methods of use thereof | Pending | 02-Apr-2024 | ||
| CA-3236572-A1 | Methods of diagnosing a synucleinopathy | Pending | 01-Nov-2021 | ||
| EP-4427039-A1 | Methods of diagnosing a synucleinopathy | Pending | 01-Nov-2021 | G01N33/6896 |
Nitrase Therapeutics Signals
Nitrase Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Breakthrough 307 | Angel Group | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Angel (individual) | Minority |
Nitrase Therapeutics FAQs
-
When was Nitrase Therapeutics founded?
Nitrase Therapeutics was founded in 2012.
-
Where is Nitrase Therapeutics headquartered?
Nitrase Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Nitrase Therapeutics?
Nitrase Therapeutics has 21 total employees.
-
What industry is Nitrase Therapeutics in?
Nitrase Therapeutics’s primary industry is Drug Discovery.
-
Is Nitrase Therapeutics a private or public company?
Nitrase Therapeutics is a Private company.
-
What is the current valuation of Nitrase Therapeutics?
The current valuation of Nitrase Therapeutics is .
-
What is Nitrase Therapeutics’s current revenue?
The current revenue for Nitrase Therapeutics is .
-
How much funding has Nitrase Therapeutics raised over time?
Nitrase Therapeutics has raised $45.9M.
-
Who are Nitrase Therapeutics’s investors?
AbbVie Ventures, Alexandria Venture Investments, Breakthrough 307, Bristol-Myers Squibb, and are 5 of 10 investors who have invested in Nitrase Therapeutics.
-
Who are Nitrase Therapeutics’s competitors?
GlycosBio, Editas Medicine, Voyager Therapeutics, PlantForm, and Dynavax Technologies are some of the 15 competitors of Nitrase Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process